ELISA/assay

Human Activin receptor type 2B (ACVR2B) ELISA Kit

MBS7250486

48-Strip-Wells

440 USD

ELISA Kit

Human Activin receptor type 2B (ACVR2B) ELISA Kit

[Activin receptor type 2B (ACVR2B)]

[Activin receptor type-2B; Activin receptor type-2B; activin receptor type-2B; activin A receptor, type IIB; Activin receptor type IIB; ACTR-IIB]

[ACVR2B]

[ACVR2B; ACVR2B; HTX4; ACTRIIB; ActR-IIB; ACTR-IIB]

AVR2B_HUMAN

Human

This assay has high sensitivity and excellent specificity for detection of ACVR2B. No significant cross-reactivity or interference between ACVR2B and analogues was observed. NOTE: Limited by current skills and knowledge, it is impossible for us to complete the cross-reactivity detection between ACVR2B and all the analogues, therefore, cross reaction may still exist in some cases.

Store all reagents at 2-8 degree C.

Typical Testing Data/Standard Curve (for reference only)

Samples: Serum, plasma, cell culture supernatants, body fluid and tissue homogenate. Assay Type: Quantitative Competitive. Sensitivity: 0.1 ng/mL.

Signal Transduction

Intended Uses: This ACVR2B ELISA kit is a 1.5 hour solid-phase ELISA designed for the quantitative determination of Human ACVR2B. This ELISA kit for research use only, not for therapeutic or diagnostic applications!. Principle of the Assay: ACVR2B ELISA kit applies the competitive enzyme immunoassay technique utilizing a polyclonal anti-ACVR2B antibody and an ACVR2B-HRP conjugate. The assay sample and buffer are incubated together with ACVR2B-HRP conjugate in pre-coated plate for one hour. After the incubation period, the wells are decanted and washed five times. The wells are then incubated with a substrate for HRP enzyme. The product of the enzyme-substrate reaction forms a blue colored complex. Finally, a stop solution is added to stop the reaction, which will then turn the solution yellow. The intensity of color is measured spectrophotometrically at 450nm in a microplate reader. The intensity of the color is inversely proportional to the ACVR2B concentration since ACVR2B from samples and ACVR2B-HRP conjugate compete for the anti-ACVR2B antibody binding site. Since the number of sites is limited, as more sites are occupied by ACVR2B from the sample, fewer sites are left to bind ACVR2B-HRP conjugate. A standard curve is plotted relating the intensity of the color (O.D.) to the concentration of standards. The ACVR2B concentration in each sample is interpolated from this standard curve.

97535735

Q13705.3

Da

Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Developmental Biology Pathway (477129); Regulation Of Signaling By NODAL Pathway (477131); Signal Transduction Pathway (477114); Signaling By Activin Pathway (730349); Signaling By BMP Pathway (106336); Signaling By NODAL Pathway (477130); Signaling Pathways Regulating Pluripotency Of Stem Cells (1026136); Signaling Pathways Regulating Pluripotency Of Stem Cells (1033502)

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptors are considered to be constitutively active kinases. This gene encodes activin A type IIB receptor, which displays a 3- to 4-fold higher affinity for the ligand than activin A type II receptor. [provided by RefSeq, Jul 2008]

ACVR2B: a tyrosine-kinase like receptor kinase of the STKR family. The holoreceptor receptor is a heteromeric complex of receptor serine kinases which include at least two type I (I and IB) and two type II (II and IIB) receptors. Each is composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic kinase domain. Type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. Type II receptor kinases are apparently constitutively active. The IIB receptor displays a 3- to 4-fold higher affinity for activin A than the II receptor. Protein type: Membrane protein, integral; Protein kinase, Ser/Thr (receptor); EC 2.7.11.30; Protein kinase, TKL; Kinase, protein; TKL group; STKR family; Type2 subfamily. Chromosomal Location of Human Ortholog: 3p22. Cellular Component: integral to plasma membrane; cytoplasm; plasma membrane; receptor complex. Molecular Function: transforming growth factor beta receptor activity; protein serine/threonine kinase activity; protein binding; growth factor binding; metal ion binding; protein serine/threonine/tyrosine kinase activity; activin binding; activin receptor activity, type II; ATP binding; receptor signaling protein serine/threonine kinase activity. Biological Process: heart development; activin receptor signaling pathway; palate development; signal transduction; protein amino acid phosphorylation; post-embryonic development; BMP signaling pathway; anterior/posterior pattern formation; positive regulation of activin receptor signaling pathway; regulation of transcription, DNA-dependent; embryonic foregut morphogenesis; pancreas development; transmembrane receptor protein serine/threonine kinase signaling pathway; lymphangiogenesis; response to glucose stimulus; mesoderm development; kidney development; gastrulation with mouth forming second; positive regulation of bone mineralization; odontogenesis of dentine-containing teeth; organ growth; positive regulation of osteoblast differentiation; insulin secretion; skeletal morphogenesis; activation of protein kinase activity; blood vessel remodeling; determination of left/right symmetry; lung development. Disease: Heterotaxy, Visceral, 4, Autosomal

48-Strip-Wells

440 USD

96-Strip-Wells

640

5x96-Strip-Wells

2895

10x96-Strip-Wells

5415